Grifols Therapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Grifols Therapeutics sits in the top decile of US sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count).
Grifols Therapeutics: 34 sponsored US clinical trials, 3 recruiting.
Grifols Therapeutics sponsors 34 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 26 completed. 15 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alpha-1 Antitrypsin Deficiency, with 2 trials.
Top-decile sponsor footprint
Grifols Therapeutics ranks in the top decile of sponsors by registered trial count (#484 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
26 of 30 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
34 total, page 1 of 1
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT07555483
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT07540221
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT05645107
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
NCT01983241
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
NCT04722887
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
NCT04547140
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
NCT04566692
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
NCT04480424
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
NCT04561115
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
NCT03451292
Alphanate in Immune Tolerance Induction Therapy
NCT03095287
Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)
NCT03351933
Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
NCT02872142
Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia
NCT02281500
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
NCT02604810
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
NCT02473952
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
NCT02473965
A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency
NCT02282527
Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass
NCT02037555
An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)
NCT02139657
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus
NCT02093221
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
NCT01684410
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
NCT01465958
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
NCT01222117
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
NCT01213043
A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion
NCT00418483
Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels
NCT00437671
A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency
NCT00389324
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
NCT00301366
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
NCT00295061
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT00220740
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
NCT00220727
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
NCT00220779
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
NCT00220766
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 15 |
| Phase 3 | 11 |
| Phase 4 | 4 |
What is open in the Grifols Therapeutics pipeline
3 recruiting of 34 indexed (9% open); 26 completed (76%).
Phase mix: 15 late (III/IV) vs 19 early (I/II) (balanced across stages).
Top condition: Alpha-1 Antitrypsin Deficiency (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Grifols Therapeutics: open-pipeline peers nationwide
Peers matched on 34 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Grifols Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 34 trials (± recruiting share)
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 34 trials · 38% recruiting
- American Regent · 34 trials · 0% recruiting
- Amicus Therapeutics · 34 trials · 15% recruiting
- Cochlear · 34 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Abbott Medical Devices · 9% recruiting · 261 trials
- Butler Hospital · 9% recruiting · 103 trials
- AMAG Pharmaceuticals · 9% recruiting · 23 trials
- Iowa State University · 9% recruiting · 23 trials
Related
What to do with this Grifols Therapeutics page
34 registered trials is a research-attention snapshot, not an endorsement of Grifols Therapeutics or any single study.
- 3 of Grifols Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alpha-1 Antitrypsin Deficiency is the condition Grifols Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alpha-1 Antitrypsin Deficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Grifols Therapeutics pipeline card: 34 registered trials from official public datasets.Report a data error.